Imagine using tiny magnetic particles as remote-controlled switches inside the brain. Instead of risky surgery to cut out damaged areas, this tech uses magnetic fields from outside the head to flip these switches and fix broken neural connections. It's like using a wireless remote to tune a radio, but for repairing brain circuits.
Current brain disorder treatments are either too invasive (surgery), too broad (electrical stimulation), or too time-sensitive (stroke drugs), leaving millions of patients with permanent deficits or drug-resistant seizures.
A mechanogenetic toolkit consisting of functionalized biocompatible magnetic nanoparticles and bioengineered synaptic mechanosensors controlled by transcranial magnetic stimulators.
If you are a hardware developer dealing with the limitations of invasive brain implants — this project developed a mechanogenetic toolkit that uses magnetic nanoparticles to stimulate the brain without surgery. This allows for subcellular resolution without needing to open the skull.
If you are a biotech firm dealing with the inability to fine-tune gene therapies based on patient response — this project developed bioengineered synaptic mechanosensors. These sensors allow for bidirectional regulation of brain circuits using external magnetic fields.
If you are a clinic dealing with the 20% of epilepsy patients who are drug-resistant — this project developed a non-invasive method to normalize neural activity. This could provide an alternative to surgical resection for patients with focal neocortical epilepsy.
Based on available project data, specific pricing or cost-per-unit information is not provided; only the EU contribution of EUR 3,543,967 for research and development is listed.
Based on available project data, the project is currently in the development and assessment phase using mouse models, meaning industrial scaling is not yet addressed.
Based on available project data, there is no specific mention of patents or licensing agreements, though the consortium includes 2 SMEs and 2 industry partners likely involved in IP development.
The technology integrates via high-permeability transcranial magnetic stimulators, which are delivered externally, avoiding the need for invasive surgical implants.
The project period runs from 2023-02-01 to 2028-01-31, with current goals focused on testing in mouse models of stroke and epilepsy.
The consortium is well-balanced for translation, consisting of 8 partners across 4 countries. With a 25% industry ratio (including 2 SMEs), the project bridges the gap between academic research (3 universities, 3 research institutes) and commercial application, ensuring that the material science and electronic components are developed with market viability in mind.
Contact Universita degli Studi di Trieste
Contact us to connect with the SynMech consortium for licensing opportunities.
